Skip to main content

Table 2 Clinical characteristics of recruited patients

From: Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: evaluation of plasma and lymphocyte expression

  Patients with fatigue (randomized) Patients without fatigue (control) p
Age (mean ± standard deviation) 48.9 ± 9.6 55.7 ± 3.8 0,08
Race    
African-American 26(81.3%) 9 (81.8%) 0.8
Caucasian 2 (6.2%) 2 (18.2%) 0.8
Stage    
I 5 (15.6%) 3 (27.3%) 0.33
II 15 (46.9%) 3 (27.3%) 0.10
III 12 (37.5%) 6 (45.4%) 0.40
Body Mass Index 23.1 ± 2 22.3 ± 1,2 p = 0.8
Histological Type    
Ductal Carcinoma 28 (87.4%) 11 (100%) 0.6
Lobular Carcinoma 2 (6.3%) - -
Metaplastic Carcinoma 2 (6.3%) - -
Hormone Receptors/HER2    
Hormone Receptor - positive, HER2 -positive 9 (28.1%) 3 (27.3%) 0.99
Hormone Receptor - positive, HER2 - negative 13 (40.7%) 5 (45.4%) 0.80
Hormone Receptor -negative, HER2 positive 1 (3.1%) 1 (9.1%) 1
Triple-negative 9 (28.1%) 2 (18.2%) 0.70
Type of Chemotherapy    
Adjuvant 18 (56.2%) 5 (45.5%) 0.40
Neoadjuvant 14 (43.8%) 6 (54.5%) 0.70
Comorbidities    
Lack of Comorbidities 26 (81.3%) 9 (81.8%) 0.80
Arterial hypertension 2 (6.2%) 2 (18.2%) 0.80
Diabetes mellitus 4 (12.5%) 0 -
Menopausal Status    
Premenopausal 13 (40.6%) 9 (81.8%) 0.10
Postmenopausal 19 (59.4%) 2 (18.2%) 0.20